The first-ever treatment for malaria in young babies and infants has been approved. On Tuesday, Novartis announced it had received approval for the treatment, Coartem Baby (known as Riamet Baby in ...
The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic. HealthDay News — A new malaria treatment has been approved for newborns and ...
Malaria kills hundreds of thousands of children annually, yet there hasn’t been a major new drug to fight it in more than 25 years. Now, Novartis says it has one. The Swiss company said Wednesday that ...
KAMPALA, Uganda (AP) — Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a ...
This October 2024 image provided by Novartis shows GanLum, a new anti-malaria treatment, at a manufacturing facility in Slovenia. (Novartis via AP) (Uncredited) NEW YORK – Researchers on Wednesday ...
At the turn of the millennium, a new class of drugs derived from ancient Chinese herbal medicine revolutionized malaria care. Artemisinin's, as they're called, are based on extracts from the sweet ...
LONDON (Reuters) -A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final ...
New research shows the malaria parasite could be developing resistance to the current front-line treatment for the disease — a drug that has saved millions of lives. An anti-malaria drug that has ...
Please provide your email address to receive an email when new articles are posted on . Pyronaridine, a common malaria drug, has been used for more than 50 years. The agent could be repurposed to ...
Advances in vaccine technology, antibody therapies, and genetic surveillance are giving researchers new tools to fight ...
NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs. Switzerland-based Novartis ...